Dalton Pharma Services Announces Manufacturing and Development Agreement with Ramsey Lake Pharma

Share Article

Dalton Pharma Services announces Agreement with Ramsey Lake Pharma for the synthesis and testing of VR23 to support their upcoming toxicology studies for their VR23 oncology candidate drug.

News Image
Dalton is very pleased to be supporting the advancement of this potentially ground-breaking cancer therapeutic.

Dalton Pharma Services today announced the signing of a drug development and manufacturing contract with Ramsey Lake Pharmaceutical Corp. (RLPC) to support toxicology studies for VR23, their novel β2-targeting proteasome inhibitor in development to treat cancer. The agreement includes the synthesis of VR23 by Dalton as well as the development of analytical testing methods and execution of a stability study.

Sean Thompson, Ramsey Lake Pharma President & CEO, commented, “We are excited to be moving our lead candidate VR23 into these critical toxicology studies with the help of an experienced, cGMP qualified pharmaceutical development partner. Dalton brings nearly 30 years of novel drug development and manufacturing experience to our program”.

Ramsey Lake Pharma is a privately held company committed to the development of novel therapies currently focused on proteasome inhibitors that improve cancer care and result in improved patient outcomes. Its lead candidate, VR23, a small molecule cancer therapeutic, shows strong potential as a next generation proteasome inhibitor, inhibiting tumor growth as a single agent. When used in combination with gold-standard anticancer drugs, VR23 can increase efficacy while reducing toxicity. VR23 also shows potential in overcoming drug resistance. The product was developed in the laboratory of Dr. Hoyun Lee of RLPC. Dr. Lee commented “It is gratifying to see our project maturing into a drug development program. We look forward to working with Dalton to get VR23 to patients.”

“Dalton is very pleased to be supporting the advancement of this potentially ground-breaking cancer therapeutic,” said Peter Pekos, CEO and President, Dalton Pharma Services. “This is a great opportunity for two Canadian companies to collaborate on developing innovative products that have the potential to dramatically improve the lives of so many cancer patients”.

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a leading cGMP contract service provider of integrated chemistry, drug development and dosage form manufacturing services to the pharmaceutical and biotechnology industries. Dalton provides expertise in medicinal chemistry, process development and reaction optimization, as well as formulation development, analytical testing and development, and cGMP manufacturing including cGMP API production and cGMP Sterile Filling Services. Dalton brings nearly 30 years of experience to every customer project, at virtually any stage of development or commercialization.
http://www.dalton.com

Dalton Contact
Peter Pekos
Dalton Pharma Services
416-661-2102
ppekos(at)dalton(dot)com

Ramsey Lake Pharma
Based in Sudbury, Ontario, Ramsey Lake Pharmaceutical Corp. (RLPC) was spun out from the Advanced Medical Research Institute of Canada (AMRIC) through its for-profit subsidiary, AMRIC Development Corp. RLPC licensed the VR23 patent portfolio from AMRIC in 2014. While the company is focusing initially on the advancement of the VR23 molecule into the clinic, it continues to build on its pipeline of other potential therapeutics. The Company is headed by Chairman, President and CEO, Sean Thompson and Chief Scientific Officer Dr. Hoyun Lee, Ph.D. in Molecular Virology, who is the inventor of VR23. RLPC was formed in 2012 by AMRIC Development Corporation, a for-profit subsidiary of the not-for-profit AMRIC, the Advanced Medical Research Institute of Canada.
http://www.ramseylakepharma.com

Ramsey Lake Pharma Media Contact
Sean Thompson
President & CEO, RLPC
Ramsey Lake Pharmaceutical Corp. (RLPC)
905-399-1086
sean(dot)thompson(at)ramseylakepharma(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Pekos
Visit website